Serum Anti-neuraminidase Antibody Responses in Human Influenza A(H1N1)pdm09 Virus Infections

Overview

Journal Emerg Microbes Infect

Specialty Infectious Diseases

Date 2019 Mar 23

PMID 30898033

Citations 6

Authors

Herath M T K Karunarathna

Ranawaka A P M Perera

Vicky J Fang

Hui-Ling Yen

Benjamin John Cowling

Malik Peiris

Affiliations

Soon will be listed here.

Abstract

Haemagglutination inhibition (HAI) antibody titres are a correlate of protection for influenza virus infection, but several studies have also demonstrated the protective role of anti-neuraminidase (anti-NA) antibodies. However, there is limited data on anti-NA antibody responses in naturally occurring human influenza. We investigated anti-NA antibody responses to pandemic N1 and seasonal N1 in 18 RT-PCR-confirmed patients with naturally acquired pandemic influenza A (H1N1) 2009 disease detected as part of a prospective community study of influenza. There were increases in neuraminidase inhibition (NAI) antibody titres to both pandemic and seasonal N1 antigens, with greater fold increases in those who had low levels of anti-pandemic N1 titres in acute sera. Of 18 patients with pandemic H1N1 infection, fourfold increases in antibody were observed by HAI in 11 (61%) patients, by anti-pandemic N1 inhibition in 13 (72%) or either in 15 of them (83%). Prior seasonal H1N1 virus infections had elicited cross-reactive anti-pandemic N1 antibody titres in some people prior to the emergence of the 2009 pandemic H1N1 virus. Antibody responses to the anti-N1 pandemic 2009 virus and cross-reactive responses to anti-seasonal N1 antibody were seen in influenza A pandemic 2009 infections. NAI antibodies can complement HAI antibody in sero-diagnosis and sero-epidemiology.

Citing Articles

Expert consensus on the benefits of neuraminidase in conventional influenza vaccines: a Delphi study.

Youhanna J, Puig-Barbera J, Miller M, Molrine D, Hadi M, Bapat S BMC Infect Dis. 2025; 25(1):53.

PMID: 39794704 PMC: 11724539. DOI: 10.1186/s12879-024-10277-4.

Novel Influenza Vaccines: From Research and Development (R&D) Challenges to Regulatory Responses.

He X, Zhang T, Huan S, Yang Y Vaccines (Basel). 2023; 11(10).

PMID: 37896976 PMC: 10610648. DOI: 10.3390/vaccines11101573.

Imprinted Anti-Hemagglutinin and Anti-Neuraminidase Antibody Responses after Childhood Infections of A(H1N1) and A(H1N1)pdm09 Influenza Viruses.

Daulagala P, Mann B, Leung K, Lau E, Yung L, Lei R mBio. 2023; 14(3):e0008423.

PMID: 37070986 PMC: 10294682. DOI: 10.1128/mbio.00084-23.

Preclinical immunogenicity assessment of a cell-based inactivated whole-virion H5N1 influenza vaccine.

Zhang Z, Jiang Z, Deng T, Zhang J, Liu B, Liu J Open Life Sci. 2022; 17(1):1282-1295.

PMID: 36249527 PMC: 9518664. DOI: 10.1515/biol-2022-0478.

Antibody Responsiveness to Influenza: What Drives It?.

Lin X, Lin F, Liang T, Ducatez M, Zanin M, Wong S Viruses. 2021; 13(7).

PMID: 34372607 PMC: 8310379. DOI: 10.3390/v13071400.

References

Hoffmann E, Neumann G, Kawaoka Y, HOBOM G, Webster R . A DNA transfection system for generation of influenza A virus from eight plasmids. Proc Natl Acad Sci U S A. 2000; 97(11):6108-13. PMC: 18566. DOI: 10.1073/pnas.100133697. View

Johnson N, Mueller J . Updating the accounts: global mortality of the 1918-1920 "Spanish" influenza pandemic. Bull Hist Med. 2002; 76(1):105-15. DOI: 10.1353/bhm.2002.0022. View

Gerdil C . The annual production cycle for influenza vaccine. Vaccine. 2003; 21(16):1776-9. DOI: 10.1016/s0264-410x(03)00071-9. View

Lambre C, Terzidis H, Greffard A, Webster R . Measurement of anti-influenza neuraminidase antibody using a peroxidase-linked lectin and microtitre plates coated with natural substrates. J Immunol Methods. 1990; 135(1-2):49-57. DOI: 10.1016/0022-1759(90)90255-t. View

Sandbulte M, Jimenez G, Boon A, Smith L, Treanor J, Webby R . Cross-reactive neuraminidase antibodies afford partial protection against H5N1 in mice and are present in unexposed humans. PLoS Med. 2007; 4(2):e59. PMC: 1796909. DOI: 10.1371/journal.pmed.0040059. View

Molinari N, Ortega-Sanchez I, Messonnier M, Thompson W, Wortley P, Weintraub E . The annual impact of seasonal influenza in the US: measuring disease burden and costs. Vaccine. 2007; 25(27):5086-96. DOI: 10.1016/j.vaccine.2007.03.046. View

Nichol K . Efficacy and effectiveness of influenza vaccination. Vaccine. 2009; 26 Suppl 4:D17-22. DOI: 10.1016/j.vaccine.2008.07.048. View

Hancock K, Veguilla V, Lu X, Zhong W, Butler E, Sun H . Cross-reactive antibody responses to the 2009 pandemic H1N1 influenza virus. N Engl J Med. 2009; 361(20):1945-52. DOI: 10.1056/NEJMoa0906453. View

Pascua P, Song M, Lee J, Park K, Kwon H, Baek Y . Evaluation of the efficacy and cross-protectivity of recent human and swine vaccines against the pandemic (H1N1) 2009 virus infection. PLoS One. 2009; 4(12):e8431. PMC: 2793524. DOI: 10.1371/journal.pone.0008431. View

10.

Cate T, Rayford Y, Nino D, Winokur P, Brady R, Belshe R . A high dosage influenza vaccine induced significantly more neuraminidase antibody than standard vaccine among elderly subjects. Vaccine. 2010; 28(9):2076-9. PMC: 2853016. DOI: 10.1016/j.vaccine.2009.12.041. View

11.

Cowling B, Chan K, Fang V, Lau L, So H, Fung R . Comparative epidemiology of pandemic and seasonal influenza A in households. N Engl J Med. 2010; 362(23):2175-2184. PMC: 4070281. DOI: 10.1056/NEJMoa0911530. View

12.

Laurie K, Carolan L, Middleton D, Lowther S, Kelso A, Barr I . Multiple infections with seasonal influenza A virus induce cross-protective immunity against A(H1N1) pandemic influenza virus in a ferret model. J Infect Dis. 2010; 202(7):1011-20. DOI: 10.1086/656188. View

13.

Ellebedy A, Ducatez M, Duan S, Stigger-Rosser E, Rubrum A, Govorkova E . Impact of prior seasonal influenza vaccination and infection on pandemic A (H1N1) influenza virus replication in ferrets. Vaccine. 2010; 29(17):3335-9. PMC: 3026885. DOI: 10.1016/j.vaccine.2010.08.067. View

14.

Wu J, Ma E, Lee C, Chu D, Ho P, Shen A . The infection attack rate and severity of 2009 pandemic H1N1 influenza in Hong Kong. Clin Infect Dis. 2010; 51(10):1184-91. PMC: 3034199. DOI: 10.1086/656740. View

15.

Marcelin G, Bland H, Negovetich N, Sandbulte M, Ellebedy A, Webb A . Inactivated seasonal influenza vaccines increase serum antibodies to the neuraminidase of pandemic influenza A(H1N1) 2009 virus in an age-dependent manner. J Infect Dis. 2010; 202(11):1634-8. PMC: 2974032. DOI: 10.1086/657084. View

16.

Cowling B, Ng S, Ma E, Cheng C, Wai W, Fang V . Protective efficacy of seasonal influenza vaccination against seasonal and pandemic influenza virus infection during 2009 in Hong Kong. Clin Infect Dis. 2010; 51(12):1370-9. DOI: 10.1086/657311. View

17.

Petrie J, Ohmit S, Johnson E, Cross R, Monto A . Efficacy studies of influenza vaccines: effect of end points used and characteristics of vaccine failures. J Infect Dis. 2011; 203(9):1309-15. PMC: 3069734. DOI: 10.1093/infdis/jir015. View

18.

Black S, Nicolay U, Vesikari T, Knuf M, Del Giudice G, Della Cioppa G . Hemagglutination inhibition antibody titers as a correlate of protection for inactivated influenza vaccines in children. Pediatr Infect Dis J. 2011; 30(12):1081-5. DOI: 10.1097/INF.0b013e3182367662. View

19.

Ohmit S, Petrie J, Cross R, Johnson E, Monto A . Influenza hemagglutination-inhibition antibody titer as a correlate of vaccine-induced protection. J Infect Dis. 2011; 204(12):1879-85. DOI: 10.1093/infdis/jir661. View

20.

Sandbulte M, Westgeest K, Gao J, Xu X, Klimov A, Russell C . Discordant antigenic drift of neuraminidase and hemagglutinin in H1N1 and H3N2 influenza viruses. Proc Natl Acad Sci U S A. 2011; 108(51):20748-53. PMC: 3251064. DOI: 10.1073/pnas.1113801108. View